MedDataX Logo

The Relationship Between the Residual Renal Function and Osteoporosis Treatment

NCT ID: NCT02304887

Last Updated: 2016-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-01-31

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The relationship between osteoporosis drugs and kidney damage is unclear. In this study, we plan to reveal relationship between osteoporosis drugs and kidney damage.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic kidney disease (CKD)- mineral and bone disorder (CKD-MBD) is one of the topic in osteoporosis treatment. As many osteoporotic patients are older, many patients are under the deterioration of the renal function. In addition, several drugs might have the potential for kidney damage. But the relationship between osteoporosis drugs and kidney damage is unclear.

The main objective of this study is to reveal relationship between osteoporosis drugs and kidney damage.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Osteoporosis Bone mineral densisty Renal function CKD-MBD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bisphosphonate

Bis, SERM Teriparatide, Denosumab

Intervention Type DRUG

Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.

Selective estrogen receptor modulator

Bis, SERM Teriparatide, Denosumab

Intervention Type DRUG

Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.

Teriparatide

Bis, SERM Teriparatide, Denosumab

Intervention Type DRUG

Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.

Senosumab

Bis, SERM Teriparatide, Denosumab

Intervention Type DRUG

Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bis, SERM Teriparatide, Denosumab

Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Osteoporosis patients

Exclusion Criteria

* eGFR \< 15
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Toshihiko Kono

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Toshihiko Kono

Head of Hospital

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rui Niimi, MD

Role: PRINCIPAL_INVESTIGATOR

Tomidahama Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tomidahama Hospital

Yokkaichi, Mie-ken, Japan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Japan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rui Niimi, MD

Role: CONTACT

Phone: (81)-59-365-0023

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Rui Niimi, MD, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB TH No 9-1

Identifier Type: -

Identifier Source: org_study_id